PURPOSE: The aim of the present study was to evaluate the potential application of a novel formulation based on a synthesized cationic lipid 2,3-di(tetradecyloxy)propan-1-amine, combined with polysorbate 80 to deliver the pCMS-EGFP plasmid into the rat retina. METHODS: We elaborated lipoplexes by mixing the formulation containing the cationic lipid and the polysorbate 80 with the plasmid at different cationic lipid/DNA ratios (w/w). Resulted lipoplexes were characterized in terms of size, charge, and capacity to condense, protect and release the DNA. In vitro transfection studies were performed in HEK-293 and ARPE-19 cells. Formulations were also tested in vivo by monitoring the expression of the EGFP after intravitreal and subretinal injections in rat eyes. RESULTS: At 2/1 cationic lipid/DNA mass ratio, the resulted lipoplexes had 200 nm of hydrodynamic diameter; were positive charged, spherical, protected DNA against enzymatic digestion and transfected efficiently HEK-293 and ARPE-19 cultured cells exhibiting lower cytotoxicity than LipofectamineTM 2000. Subretinal administrations transfected mainly photoreceptors and retinal pigment epithelial cells; whereas intravitreal injections produced a more uniform distribution of transfection through the inner part of the retina. CONCLUSIONS: These results hold great expectations for other gene delivery formulations based on this cationic lipid for retinal gene therapy purposes.
PURPOSE: The aim of the present study was to evaluate the potential application of a novel formulation based on a synthesized cationic lipid2,3-di(tetradecyloxy)propan-1-amine, combined with polysorbate 80 to deliver the pCMS-EGFP plasmid into the rat retina. METHODS: We elaborated lipoplexes by mixing the formulation containing the cationic lipid and the polysorbate 80 with the plasmid at different cationic lipid/DNA ratios (w/w). Resulted lipoplexes were characterized in terms of size, charge, and capacity to condense, protect and release the DNA. In vitro transfection studies were performed in HEK-293 and ARPE-19 cells. Formulations were also tested in vivo by monitoring the expression of the EGFP after intravitreal and subretinal injections in rat eyes. RESULTS: At 2/1 cationic lipid/DNA mass ratio, the resulted lipoplexes had 200 nm of hydrodynamic diameter; were positive charged, spherical, protected DNA against enzymatic digestion and transfected efficiently HEK-293 and ARPE-19 cultured cells exhibiting lower cytotoxicity than LipofectamineTM 2000. Subretinal administrations transfected mainly photoreceptors and retinal pigment epithelial cells; whereas intravitreal injections produced a more uniform distribution of transfection through the inner part of the retina. CONCLUSIONS: These results hold great expectations for other gene delivery formulations based on this cationic lipid for retinal gene therapy purposes.
Authors: C Mussolino; M della Corte; S Rossi; F Viola; U Di Vicino; E Marrocco; S Neglia; M Doria; F Testa; R Giovannoni; M Crasta; M Giunti; E Villani; M Lavitrano; M L Bacci; R Ratiglia; F Simonelli; A Auricchio; E M Surace Journal: Gene Ther Date: 2011-03-17 Impact factor: 5.250
Authors: Noha Attia; Mohamed Mashal; Cristina Soto-Sánchez; Gema Martínez-Navarrete; Eduardo Fernández; Santiago Grijalvo; Ramón Eritja; Gustavo Puras; Jose Luis Pedraz Journal: Drug Des Devel Ther Date: 2018-11-16 Impact factor: 4.162